文献速递造血干细胞移植与细胞治疗血栓与止血

异基因造血干细胞移植后经典型与晚发型肝窦阻塞综合征/静脉闭塞病的日本移植登记分析

Classical and Late-Onset SOS/VOD After Allogeneic HSCT: A Japanese Transplant Registry Analysis.
PubMed 文献 · Am J Hematol · 2025-05-19

该回顾性研究利用日本全国登记数据纳入16518例异基因造血干细胞移植受者,分析经典型与晚发型肝窦阻塞综合征/静脉闭塞病(SOS/VOD)的发病率、危险因素及对移植结局的影响,发现两型累积发病率分别为2.5%和2.2%,中位发病时间分别为移植后13天和42天,均与更差的总生存显著相关,但危险因素不同。

要点

  • 经典型与晚发型SOS/VOD累积发病率分别为2.5%和2.2%,中位发病时间为移植后13天和42天。
  • 经典型(HR 3.45;95%CI 3.07-3.87)与晚发型(HR 3.98;95%CI 3.51-4.51)SOS/VOD均与更差的总生存显著相关。
  • 两型危险因素不同,同时使用白消安和美法仑预处理者晚发型SOS/VOD发病率更高。

核心结论

  • 经典型与晚发型SOS/VOD在发病率、发病时间和危险因素上存在差异,提示对两类高危患者需采取不同的监测和治疗策略。

研究设计与样本

  • 回顾性研究,利用日本全国移植登记数据纳入16518例异基因造血干细胞移植受者,分析经典型与晚发型SOS/VOD的发病率、危险因素及对移植结局的影响。

主要发现

  • 经典型与晚发型SOS/VOD的累积发病率分别为2.5%和2.2%,中位发病时间分别为移植后13天和42天。
  • 经典型SOS/VOD患者总生存较无SOS/VOD者显著更差(HR 3.45;95%CI 3.07-3.87)。
  • 晚发型SOS/VOD患者总生存较无SOS/VOD者显著更差(HR 3.98;95%CI 3.51-4.51)。
  • 肝脏合并症、高危疾病、使用美法仑(MEL)和清髓性预处理与两型SOS/VOD均相关。
  • 体能状态差、既往移植史和丙型肝炎病毒阳性仅与经典型SOS/VOD相关;脐带血或相关人类白细胞抗原单倍体供者、使用全身照射和白消安(BU)、以及基于他克莫司的移植物抗宿主病预防仅与晚发型SOS/VOD相关。

关键数值与推荐

  • 采用2016年欧洲血液与骨髓移植学会标准将SOS/VOD分为经典型和晚发型。
  • 同时使用含白消安和美法仑预处理方案的患者晚发型SOS/VOD发病率更高。

临床怎么用

  • 作者认为,针对经典型和晚发型SOS/VOD高危的异基因造血干细胞移植受者,可能需要不同的监测和治疗方式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). According to the 2016 European Society for Blood and Marrow Transplantation criteria, SOS/VOD is classified into classical SOS/VOD and late-onset SOS/VOD, but their similarities and differences remain unclear. Here we retrospectively investigated the incidence, risk factors, and impact on transplant outcomes of classical and late-onset SOS/VOD in 16 518 allo-HSCT recipients using the Japanese nationwide registry data. The cumulative incidences of classical and late-onset SOS/VOD were 2.5% and 2.2%, with a median onset of 13 and 42 days after transplantation, respectively. Both patients with classical (hazard ratio [HR], 3.45; 95% CI, 3.07-3.87) and late-onset (HR, 3.98; 95% CI, 3.51-4.51) SOS/VOD had a significantly worse overall survival compared with those without. The risk factors for classical and late-onset SOS/VOD are different. Hepatic comorbidities, high-risk diseases, use of melphalan (MEL), and myeloablative conditioning are associated with both types of SOS/VOD. Whereas poor performance status, a prior history of transplantation, and positive hepatitis C virus are associated with only classical SOS/VOD, allo-HSCT from cord blood or related human leukocyte antigen-haploidentical donors, use of total body irradiation and busulfan (BU), and tacrolimus-based graft-versus-host disease prophylaxis are associated with only late-onset SOS/VOD. In particular, the incidence of late-onset SOS/VOD is much higher in patients receiving both BU- and MEL-containing conditioning regimens. These findings suggest that different monitoring and treatment approaches are necessary for allo-HSCT recipients at high risk for classical and late-onset SOS/VOD.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Masuda K, Kataoka K, Sakurai M, et al. Classical and Late-Onset SOS/VOD After Allogeneic HSCT: A Japanese Transplant Registry Analysis. Am J Hematol. 2025. PMID: 40387331. doi:10.1002/ajh.27715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。